Terug
Ook genoteerd als
IPSEF
OTC
Dagbereik
€ 43,09
€ 43,23
52-Weeksbereik
€ 25,11
€ 49,45
Volume
1
50D / 200D Gem.
€ 42,78
/
€ 35,78
Vorige Slotkoers
€ 44,63
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 133,5 | 0,4 |
| P/B | 13,2 | 2,9 |
| ROE % | 10,0 | 3,8 |
| Net Margin % | 12,1 | 3,9 |
| Rev Growth 5Y % | 6,5 | 10,0 |
| D/E | 0,2 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 3,84
€ 3,50 – € 4,11
|
4,8 B | 1 |
| FY2029 |
€ 3,70
€ 3,36 – € 3,95
|
4,6 B | 1 |
| FY2028 |
€ 3,27
€ 2,97 – € 3,50
|
4,6 B | 1 |
Belangrijkste Punten
Revenue grew 6,46% annually over 5 years — modest growth
Earnings grew 23,43% over the past year
ROE of 10,03% — decent returns on equity
Debt/Equity of 0,24 — conservative balance sheet
Generating 992,33M in free cash flow
P/E of 133,45 — premium valuation
Groei
Revenue Growth (5Y)
6,46%
Revenue (1Y)-1,22%
Earnings (1Y)23,43%
FCF Growth (3Y)20,54%
Kwaliteit
Return on Equity
10,03%
ROIC9,98%
Net Margin12,09%
Op. Margin20,30%
Veiligheid
Debt / Equity
0,24
Current Ratio1,96
Interest Coverage20,67
Waardering
P/E Ratio
133,45
P/B Ratio13,15
EV/EBITDA78,83
Dividend Yield0,01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -1,22% | Revenue Growth (3Y) | 3,34% |
| Earnings Growth (1Y) | 23,43% | Earnings Growth (3Y) | -18,60% |
| Revenue Growth (5Y) | 6,46% | Earnings Growth (5Y) | -9,86% |
| Profitability | |||
| Revenue (TTM) | 3,53B | Net Income (TTM) | 426,96M |
| ROE | 10,03% | ROA | 6,16% |
| Gross Margin | 70,58% | Operating Margin | 20,30% |
| Net Margin | 12,09% | Free Cash Flow (TTM) | 992,33M |
| ROIC | 9,98% | FCF Growth (3Y) | 20,54% |
| Safety | |||
| Debt / Equity | 0,24 | Current Ratio | 1,96 |
| Interest Coverage | 20,67 | Dividend Yield | 0,01% |
| Valuation | |||
| P/E Ratio | 133,45 | P/B Ratio | 13,15 |
| P/S Ratio | 16,14 | PEG Ratio | 1,09 |
| EV/EBITDA | 78,83 | Dividend Yield | 0,01% |
| Market Cap | 56,98B | Enterprise Value | 56,51B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 3,53B | 3,57B | 3,31B | 3,16B | 2,75B |
| Net Income | 426,96M | 345,90M | 644,40M | 648,60M | 646,60M |
| EPS (Diluted) | 1,28 | 1,04 | 1,85 | 1,79 | 1,89 |
| Gross Profit | 2,49B | 2,96B | 2,74B | 2,63B | 2,31B |
| Operating Income | 716,85M | 496,70M | 816,00M | 729,90M | 824,70M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 6,93B | 6,44B | 6,32B | 5,61B | 5,01B |
| Total Liabilities | 2,60B | 2,26B | 2,50B | 2,27B | 2,25B |
| Shareholders' Equity | 4,33B | 4,18B | 3,83B | 3,34B | 2,74B |
| Total Debt | 1,05B | 426,80M | 373,50M | 771,60M | 693,10M |
| Cash & Equivalents | 1,52B | 678,10M | 528,40M | 1,17B | 814,70M |
| Current Assets | 2,82B | 2,02B | 1,90B | 2,40B | 1,95B |
| Current Liabilities | 1,44B | 1,51B | 1,63B | 1,34B | 1,23B |